

## CLAIMS

What is claimed is:

1. A process for cancer immunotherapy that utilizes a succession of antitumor antibodies prepared from different species.
2. According to claim 1 the species of animals used to prepare the antitumor antibodies include: horse, donkey, cow, goat, sheep, rabbit, turkey, chicken, rat, mice and other animal species including human autoantibodies.
3. According to claim 1 the term "tumor antigen" includes all types of antigen found in tumors including those shared by normal cells such as tumor associated antigens, cluster determinant (CD) markers, and intracellular components such as nuclear and cytoplasmic material released by dead tumor cells into the surrounding environment.
4. According to claim 1 the term "antitumor antibody" includes all types of polyclonal and monoclonal antibodies .
5. According to claim 5 the antitumor antibodies may consist of the whole IgG molecule or the whole IgM molecule or the binding Fab and F(ab)<sub>2</sub> fragments of the antibody.

6. According to claim 1-5 the cancer patient is pre-tested by laboratory testing and by skin testing against the species animal immunoglobulin to determine non-reactivity before treatment with the antitumor antibody.
7. According to claims 1-6 a process of cancer treatment utilizing a therapeutic dosage of a variety of radionuclides linked to carrier antitumor antibodies from different species which is injected into the cancer patient.
8. According to claims 1-6 a process of cancer treatment utilizing a variety of cytotoxic anti-cancer drugs linked to carrier antitumor antibodies from different species which is injected into the cancer patient.
9. According to claims 1-6 a process of cancer treatment utilizing a variety of biological response modifiers linked to carrier antitumor antibodies which is injected into the cancer patient.
10. According to claims 1-6 a process of cancer treatment utilizing a variety of toxins linked to carrier antitumor antibodies which is injected into the cancer patient.
11. According to claims 1-6 a process of cancer treatment utilizing a variety of blood vessel growth inhibiting compounds linked to carrier antitumor antibodies which is injected into the cancer patient.
12. According to claims 1-11 a process of cancer treatment whereby the cancer patient receives a single pharmaceutical linked to different species antibodies directed against a specific antigen.

13. According to claims 1-11 a process of cancer treatment whereby the cancer patient receives a single pharmaceutical linked to different species antibodies directed against multiple antigens.
14. According to claims 1-11 a process of cancer treatment whereby the cancer patient receives different pharmaceuticals linked to different species antibodies directed against a specific antigen.
15. According to claims 1-11 a process of cancer treatment whereby the cancer patient receives different pharmaceuticals linked to different species antibodies directed against multiple antigens.
16. According to claims 1-6 a process of cancer treatment whereby the cancer patient receives a pre-targeting injection of antitumor antibody from one animal species, followed by later injections of radionuclide labeled antibody and/ or drug labeled antibody prepared in a different species and directed against the immunoglobulin component of the first animal species.
17. According to claims 1-6 a process of cancer treatment whereby the cancer patient is only exposed once to the antibody from a particular animal species which minimizes the risk of the patient developing an allergic reaction to the therapeutic antibodies.